<DOC>
	<DOC>NCT01360554</DOC>
	<brief_summary>This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.</brief_summary>
	<brief_title>ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Evidence of pathologically confirmed, advanced NSCLC (with known histology). Prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced NSCLC). Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses. Adequate renal, hematologic, liver function. ECOG PS of 02. Radiologically measurable disease. Small cell histology. Symptomatic brain mets or known leptomeningeal mets. Prior therapy with agent known or proposed to be active by action on EGFR tyrosine kinase or other HER family proteins. Uncontrolled medical disorders.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>comparative study of PF-00299804 and Erlotinib</keyword>
	<keyword>Double-Blind Phase 3 trial of TKI</keyword>
</DOC>